Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KENT J STOCK

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1356331904
CMS profile
60765
Location
CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,393.79

57 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,230.11 53
Education $125.94 3
Consulting Fee $37.74 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KENT J STOCK

NPI 1356331904 · CMS profile ID 60765

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356331904?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KENT J STOCK, NPI 1356331904, CMS profile ID 60765. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356331904?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KENT J STOCK, NPI 1356331904, CMS profile ID 60765. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356331904?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KENT J STOCK, NPI 1356331904, CMS profile ID 60765, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1356331904?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

57 matching records · $1,393.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 57 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–57 of 57.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $17.4202/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048403357 CMS
Insmed, Inc. $21.7201/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978815021 CMS
Insmed, Inc. $5.9501/25/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978823615 CMS
Astellas Pharma US Inc $24.7601/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033866279 CMS
AbbVie Inc. $27.9401/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999130209 CMS
ViiV Healthcare Company $20.2901/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001149159 CMS
Merck Sharp & Dohme LLC $17.3601/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048866635 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $995.95 67
PY2020 $969.14 60
PY2021 $1,091.35 54
PY2022 $1,147.03 58
PY2023 $1,393.79 57
PY2024 $1,186.13 53
PY2025 $861.88 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $58,426.26 34
PY2024 Principal investigator $216,962.12 136
PY2023 Principal investigator $126,340.56 34
PY2022 Principal investigator $190,972.22 47
PY2021 Principal investigator $271,869.10 20
PY2020 Principal investigator $8,500.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Insmed, Inc. $6,888.84 07/23/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646360
Principal investigator 1 Insmed, Inc. $0.44 07/23/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646362
Principal investigator 1 Insmed, Inc. $0.46 07/23/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646364
Principal investigator 1 Insmed, Inc. $0.46 06/16/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646352
Principal investigator 1 Insmed, Inc. $0.66 05/28/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646350
Principal investigator 1 Insmed, Inc. $0.46 05/28/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646354
Principal investigator 1 Insmed, Inc. $11,481.40 05/28/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646356
Principal investigator 1 Insmed, Inc. $0.92 05/28/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646358
Principal investigator 1 Insmed, Inc. $0.88 03/05/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646300
Principal investigator 1 Insmed, Inc. $16,073.96 03/05/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646308
Principal investigator 1 Insmed, Inc. $0.46 03/05/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646318
Principal investigator 1 Insmed, Inc. $0.92 03/05/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646328
Principal investigator 1 Insmed, Inc. $0.44 03/03/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646302
Principal investigator 1 Insmed, Inc. $6,888.84 03/03/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646310
Principal investigator 1 Insmed, Inc. $0.46 03/03/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646320
Principal investigator 1 Insmed, Inc. $0.46 03/03/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646322
Principal investigator 1 Insmed, Inc. $180.36 02/21/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646340
Principal investigator 1 Insmed, Inc. $882.36 02/21/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646342
Principal investigator 1 Insmed, Inc. $882.36 02/21/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646344
Principal investigator 1 Insmed, Inc. $180.36 02/21/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646346
Principal investigator 1 Insmed, Inc. $180.36 02/21/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646348
Principal investigator 1 Insmed, Inc. $0.44 02/18/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646304
Principal investigator 1 Insmed, Inc. $6,888.84 02/18/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646312
Principal investigator 1 Insmed, Inc. $0.46 02/18/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646314
Principal investigator 1 Insmed, Inc. $0.46 02/18/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646324
Principal investigator 1 Insmed, Inc. $0.44 02/05/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646298
Principal investigator 1 Insmed, Inc. $6,888.84 02/05/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646306
Principal investigator 1 Insmed, Inc. $0.46 02/05/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646316
Principal investigator 1 Insmed, Inc. $0.46 02/05/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646326
Principal investigator 1 Insmed, Inc. $100.00 01/24/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646330
Principal investigator 1 Insmed, Inc. $200.00 01/24/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646332
Principal investigator 1 Insmed, Inc. $200.00 01/24/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646334
Principal investigator 1 Insmed, Inc. $300.00 01/24/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646336
Principal investigator 1 Insmed, Inc. $200.00 01/24/2025 Non-covered Recipient Entity
Lowcountry Infectious Diseases PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646338